Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Advanced hormone-sensitive breast cancer: overcoming resistance.

Journal of the National Comprehensive Cancer Network : JNCCN - 1 May 2015

Mayer Ingrid A

Abstract excerpt

Novel strategies to overcome resistance to endocrine therapy are on the horizon, especially PI3K inhibitors, CDK 4/6 inhibitors, and agents targeting methylation. However, many, if not most, patients with progressive estrogen receptor-positive breast cancer will continue to show response to multiples lines of endocrine therapy alone. Which patient subsets will be candidates for the emerging agents is still...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Hormonal
Share to Breast Neoplasms
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Molecular Targeted Therapy

Share to Mutation

Share to Phosphatidylinositol 3-Kinases

Share to Protein Kinase Inhibitors

Share to Receptors, Estrogen

Source

Identifiers

PMID: 25995422
DOI: 10.6004/jnccn.2015.0195

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Advanced hormone-sensitive breast cancer: overcoming resistance.PMID 25995422Read ↗

Metastatic ER+ Breast Cancer: Mechanisms of Resistance and Future Therapeutic ApproachesSemantic proximity Read ↗

Molecular Mechanisms and Therapeutic Strategies to Overcome Resistance to Endocrine Therapy and CDK4/6 Inhibitors in Advanced ER+/HER2- Breast CancerSemantic proximity Read ↗

Breast Cancer, HER2 Mutations, and Overcoming Drug Resistance.Semantic proximity Read ↗

New agents for endocrine resistance in breast cancer.Semantic proximity Read ↗

New drugs for breast cancer subtypes: Targeting driver pathways to overcome resistanceSemantic proximity Read ↗

How I treat endocrine-dependent metastatic breast cancer.Semantic proximity Read ↗

The Future of ER+/HER2- Metastatic Breast Cancer Therapy: Beyond PI3K Inhibitors.Semantic proximity Read ↗

A predictive endocrine resistance index accurately stratifies luminal breast cancer treatment responders and nonresponders.Semantic proximity Read ↗

Endocrine resistance in hormone-responsive breast cancer: mechanisms and therapeutic strategies.Semantic proximity Read ↗

Development and validation of multivariate predictors of primary endocrine resistance to tamoxifen and aromatase inhibitors in luminal breast cancer reveal drug-specific differencesSemantic proximity Read ↗

Endocrine-resistant breast cancer: underlying mechanisms and strategies for overcoming resistance.Semantic proximity Read ↗

De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistanceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.